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Abstract: Tumors strongly depend on their surrounding tumor microenvironment (TME) for growth
and progression, since stromal elements are required to generate the optimal conditions for cancer
cell proliferation, invasion, and possibly metastasis. Prostate cancer (PCa), though easily curable
during primary stages, represents a clinical challenge in advanced stages because of the acquisition of
resistance to anti-cancer treatments, especially androgen-deprivation therapies (ADT), which possibly
lead to uncurable metastases such as those affecting the bone. An increasing number of studies
is giving evidence that prostate TME components, especially cancer-associated fibroblasts (CAFs),
which are the most abundant cell type, play a causal role in PCa since the very early disease stages,
influencing therapy resistance and metastatic progression. This is highlighted by the prognostic
value of the analysis of stromal markers, which may predict disease recurrence and metastasis.
However, further investigations on the molecular mechanisms of tumor–stroma interactions are
still needed to develop novel therapeutic approaches targeting stromal components. In this review,
we report the current knowledge of the characteristics and functions of the stroma in prostate
tumorigenesis, including relevant discussion of normal prostate homeostasis, chronic inflammatory
conditions, pre-neoplastic lesions, and primary and metastatic tumors. Specifically, we focus on the
role of CAFs, to point out their prognostic and therapeutic potential in PCa.
Keywords: prostate cancer; reactive stroma; tumor microenvironment; bone metastasis; cancer
associated fibroblasts
1. Introduction
The organization of animal tissues is maintained by communication of epithelial cells with each
other and the surrounding cellular and non-cellular stromal components. In carcinomas, this homeostasis
is disrupted, leading to the generation of an abnormal tumor microenvironment (TME) that influences
tumor progression [1]. The presence of an altered TME can be sufficient to promote epithelial cell
tumorigenesis even in the absence of genetic alterations [2]. Interestingly, cancer cells originating within a
tumor-causing stroma may lose their tumorigenicity when introduced into a normal microenvironment [1,2].
This highlights the strong dependency of cancer cell behavior on the local microenvironment. Cancer cells
and adjacent stromal cells are subjected to selective pressure in order to face growth-limiting conditions
such as exposure to carcinogens, hypoxia, inflammation, or chemotherapeutic drugs [3]. These conditions
might eventually result in co-evolution of tumor and stromal components towards the selection of cancer
cells with aggressive traits and the generation of a pro-tumorigenic environment [4].
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The TME is a system composed of different components that include fibroblasts, endothelial cells,
pericytes, immune cells, and extracellular matrix (ECM) proteins [5]. Cancer cells establish a crosstalk
with these stromal components through many signaling factors such as cytokines, chemokines, and
growth factors [6].
Prostate cancer (PCa) represents a major clinical problem, as the cancer type with the third-highest
incidence in the male population worldwide and the third leading cause of cancer-related death
among men in Europe [7,8]. The majority of PCa are classified as adenocarcinoma, since they originate
from epithelial cells of the prostatic gland [9]. Androgen dependency has led to the use of androgen
deprivation therapies (ADT) in combination with other therapeutic approaches such as chemotherapy,
radiotherapy, and/or immunotherapy [10,11]. PCa may develop resistance to ADT and this is often
accompanied by the development of metastasis [12], which represents more than 90% of PCa related
deaths [13]. The mechanisms of interactions between stromal and epithelial cells are poorly defined
in PCa. However, increasing evidence shows that stromal cells can significantly contribute to the
development of castration-resistant prostate cancer (CRPC) [14,15]. The tumor/stroma ratio and the
expression of stromal markers represent valuable prognostic tools to determine PCa progression and
predict therapy response [16], highlighting the importance of the stroma in tumorigenesis.
Cancer-associated fibroblasts (CAFs), which are the most abundant stromal cell population,
play a crucial role in PCa development and aggressiveness [17]. In vitro and in vivo experiments have
demonstrated that CAFs promote tumor progression of low tumorigenic prostate adenocarcinoma cells,
sustaining their growth and leading to castration resistance and eventually bone metastasis [18,19].
Prostate adenocarcinoma preferentially forms bone metastasis, unlike neuroendocrine PCa that can
also metastasize to soft tissues such as lung or liver tissues [20,21]. It is increasingly evident that organ
tropism of PCa metastasis depends on the interactions between cancer cells and the resident stromal
cells at the metastatic site, in agreement with the ‘seed and soil’ paradigm of Paget [22]. In this context
the molecular characteristics of disseminated prostate adenocarcinoma cells and bone-resident stromal
cells favor the establishment of suitable signaling networks and microenvironments that represent the
‘soil’ for PCa cell survival and proliferation [23].
Further understanding of the molecular mechanisms of PCa cell interactions with the stroma
during tumor initiation, progression, and metastasis may provide relevant insights into new therapeutic
approaches to overcome therapy resistance and tumor metastasis. In this review, we focus on the role
of the TME, and in particular of CAFs and ECM proteins, during prostate homeostasis, benign prostatic
hyperplasia, prostatic intraepithelial lesions, primary PCa, and bone metastasis in order to elucidate
the stromal contribution in different prostate disease contexts.
2. Cancer-Associated Fibroblasts (CAFs)
Fibroblasts are cells derived mainly from the mesenchyme, a tissue of mesodermal origin composed
by loosely associated cells surrounded by extracellular matrix (ECM) [24]. During normal development
and physiology, fibroblasts are the major source of ECM components. However, due to the lack of
fibroblast-specific markers, they are often defined by a combination of morphology, tissue position,
and lack of markers for epithelial cells, endothelial cells, and leukocytes. Vimentin and platelet-derived
growth factor receptor -α (PDGFR-α) are commonly used, in combination with cell location and
morphology, as markers to define fibroblasts, although their expression is not only restricted to fibroblasts.
Vimentin is an intermediate filament protein that is considered to be the major cytoskeletal component
of mesenchymal cells [25]. PDGFs are potent mitogenic factors for cells of mesenchymal origin; binding
of PDGFs to their receptors (PDGFR-α or -β) stimulates fibroblast proliferation, which is especially
required during the wound healing process [26]. Fibroblasts participate in this process by secreting
ECM components such as collagen type-I and -III, allowing repair through the formation of the so called
‘granulation tissue’ [27]. Following tissue damage, mechanical stress, fibronectin, and transforming
growth factor -β (TGF-β) secretion induce the transition of fibroblasts into myofibroblasts (MFBs) [27].
MFBs are highly contractile fibroblasts characterized by co-expression of vimentin and α-smooth muscle
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actin (α-SMA), a marker typical of smooth muscle cells (Figure 1). Through the synthesis of ECM
components and due to their contractile phenotype, MFBs induce the contraction of the granulation
tissue to favor wound closure [27]. Thereafter, they undergo apoptosis when epithelialization occurs [27].
Fibroblasts are also fundamental for inducing angiogenesis by secreting angiogenic factors such as
vascular endothelial growth factor (VEGF) and matrix proteins [28]. They also coordinate immune
system activity through the production of cytokines and chemokines [29]. Finally, fibroblasts play a key
role in the control of tissue homeostasis because in both normal conditions and following injury they
continuously interact with epithelial cells to control local epithelial stem cell behavior [30]. All of these
functions are fundamental to create a growth-promoting microenvironment that ensures tissue repair.
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vimentin) and smooth muscle cells (expressing α-SMA, calponin and desmin). Epithelial-stromal cell 
interaction maintains tissue homeostasis, smooth-muscle cell differentiation and inhibits epithelial 
cell proliferation. Tumor-initiating events (e.g., epithelial cell genetic alterations, chronic 
inflammation) increase luminal cell proliferation, potentially leading to the development of 
high-grade prostatic intraepithelial neoplasia (PIN). In this condition, the stroma is characterized by 
low smooth muscle cells and the presence of myofibroblasts (MFBs) (co-expressing vimentin and 
α-SMA). Epithelial cells release TGFβ ligands, Kallikrein-related peptidase-4 (KLK4), extracellular 
vesicles (EVs) and possibly other factors, inducing normal fibroblast transition into MFBs, increased 
extracellular matrix (ECM) component deposition (e.g., collagen, fibronectin) and TNC secretion, 
typical characteristics of reactive stroma. Disruption of the basal cell layer leads to PCa and is a 
pre-requisite for tumor cell invasiveness. In primary PCa, fibroblasts and MFBs acquire 
pro-tumorigenic properties, thus being defined as cancer-associated fibroblasts (CAFs) (which are a 
heterogenous cellular population expressing several markers such as FAP, PDGFRB, FSP-1, and 
α-SMA). Due to the change in the cellular composition of reactive stroma, the immunohistochemistry 
of primary PCa tissue samples is typically characterized by lower calponin and desmin expression, 
increased vimentin staining (due to the high number of fibroblasts, especially CAFs) and 
Figure 1. Tumor–stroma interactions in primary prostate cancer (PCa) progression. Simplified representation
of the epithelial and stromal components and their interactions during primary PCa tumorigenesis (blood
vessels and immune cells are not reported). In normal conditions, the epithelium is highly organized with
the basement membrane separating basal and luminal cells from the underlying stroma. The main cellular
components of the stroma are fibroblasts (expressing vimentin) and smooth muscle cells (expressingα-SMA,
calponin and desmin). Epithelial-stromal cell interaction maintains tissue homeostasis, smooth-muscle cell
differentiation and inhibits epithelial cell proliferation. Tumor-initiating events (e.g., epithelial cell genetic
alterations, chronic inflammation) increase luminal cell proliferation, potentially leading to the development
of high-grade prostatic intraepithelial neoplasia (PIN). In this condition, the stroma is characterized by
low smooth muscle cells and the presence of myofibroblasts (MFBs) (co-expressing vimentin and α-SMA).
Epithelial cells release TGFβ ligands, Kallikrein-related peptidase-4 (KLK4), extracellular vesicles (EVs)
and possibly other factors, inducing normal fibroblast transition into MFBs, increased extracellular matrix
(ECM) component deposition (e.g., collagen, fibronectin) and TNC secretion, typical characteristics of
reactive stroma. Disruption of the basal cell layer leads to PCa and is a pre-requisite for tumor cell
invasiveness. In primary PCa, fibroblasts and MFBs acquire pro-tumorigenic properties, thus being defined
as cancer-associated fibroblasts (CAFs) (which are a heterogenous cellular population expressing several
markers such as FAP, PDGFRB, FSP-1, and α-SMA). Due to the change in the cellular composition of
reactive stroma, the immunohistochemistry of primary PCa tissue samples is typically characterized by
lower calponin and desmin expression, increased vimentin staining (due to the high number of fibroblasts,
especially CAFs) and co-localization of vimentin and α-SMA (indicating MFBs and CAFs). CAFs establish
a paracrine communication with cancer cells through the release of factors such as IL-6, IL-8, TGFβ, FGFs,
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VEGF, and GDF15, stimulating tumor growth, angiogenesis, and progression. Moreover, they activate
YAP and Hedgehog (Hh) signaling and express NADPH-oxidase 4 (Nox4), which induces reactive oxygen
species (ROS) production. Direct CAF–cancer cell contact enhances cancer cell motility through Eph-Ephrin
signaling. Eventually, CAFs promote tumor invasion by inducing epithelial-to-mesenchymal transition
(EMT), e.g., through the release of factors such as matrix-metalloproteinases (MMPs) or EVs containing
microRNA-409 (miR-409), potentially leading to metastasis.
CAFs share multiple similarities with fibroblasts during wound healing, but they have distinct
properties from normal fibroblasts or MFBs, due to their involvement in carcinogenesis through
the generation of a ‘reactive stroma’ [31,32]. Reactive stroma is a term used to define the set of
pro-tumorigenic alterations that occur in the TME as a specific ‘reaction’ to tumor cells. The reactive
stroma is characterized by the presence of ‘MFB-like’ CAFs, altered ECM deposition, neovascularization
and immune cell infiltration, similarly to a wound healing niche [31]. However, while normal wound
healing is a controlled process that resolves when tissue has regenerated, tumors displace the normal
stroma and maintain this type of microenvironment indefinitely in order to exploit its growth-promoting
properties [31]. For this reason, tumors have been termed ‘wounds that do not heal’ [33].
According to this view, CAFs predominantly originate from the local fibroblasts surrounding
the pre-neoplastic lesion [34]. However, some studies have demonstrated that CAFs can also have
alternative origins: bone marrow-derived mesenchymal stem cells or adipocytes can be recruited to
the TME and converted into CAFs [35,36].
CAFs are characterized by molecular markers that are upregulated compared to normal fibroblasts,
such as fibroblast activation protein (FAP), PDGFR-β, fibroblast-specific protein-1 (FSP-1) (also known
as S100A4), and α-SMA (Figure 1, Table 1) [37]. Expression of these markers can also define distinct
CAF subpopulations and this heterogeneity may be explained by the different cellular origins of
CAFs. However, these markers are not fibroblast-specific, making CAFs difficult to define [37,38].
The simplest view is that CAFs are those cells associated with the TME that are negative for epithelial,
endothelial, and leukocyte markers; present an elongated morphology; and lack mutations found
within cancer cells. This latter feature is important to exclude that they are cancer cells which have
undergone a profound epithelial to mesenchymal transition (EMT) [24].
In the reactive stroma, CAFs mediate ECM deposition and remodeling through secretion of several
ECM proteins such as collagens, fibronectin, tenascin, and periostin [31]. CAF remodeling activity
increases tissue stiffness and induces mechanical stress [24]. These changes of ECM properties stimulate
cancer cell proliferation and lead to hypoxia, which promotes tumor aggressiveness [24]. In addition,
CAFs represent a fundamental source of growth factors, cytokines, and exosomes, which stimulate
tumor growth and invasiveness (Figure 1) and affect therapy response [24,39]. Examples of factors
released by CAFs are TGF-β, fibroblast growth factors (FGFs), hepatocyte growth factor (HGF),
interleukin-6 (IL-6), and growth differentiation factor 15 (GDF15) [32,40,41].
Table 1. CAF markers.
Gene Symbol Protein Name
Expression in
CAFs vs Normal
Fibroblasts
Methods for Gene
Expression Evaluation Reference
ACTA2 α-smooth actin (α-SMA) Upregulated RT-qPCR, IHC ontissue microarrays [42,43]
ASPN Asporin Upregulated
Tag-based RNA
profiling, microarray
profiling, IHC, RT-qPCR
[38,44,45]
CAV1 Caveolin-1 Downregulated Tag profiling,IHC, RT-qPCR [38]
COL1A1 Collagen Type-I Upregulated RT-qPCR, IHC [42,43]
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Table 1. Cont.
Gene Symbol Protein Name
Expression in
CAFs vs Normal
Fibroblasts
Methods for Gene
Expression Evaluation Reference
CXCL12
Stromal cell-derived factor 1
(SDF1)/ (C-X-C motif
chemokine ligand 12
(CXCL12)
Upregulated Tag-profiling,RT-qPCR, ELISA [38,46]
FAP Fibroblast activation protein Upregulated IHC [42]
FGF2, FGF7, FGF10 Fibroblast growthfactor-2/-7/-10 Upregulated
RT-qPCR,
Western Blot, IHC [43,47,48]
FN1 Fibronectin Upregulated Tag profiling,IHC, RT-qPCR [38]
ITGA1 Integrin-α1 (CD49a) Upregulated IHC [49]
OGN Osteoglycin Upregulated Tag-profiling,IHC, RT-qPCR [38]
PDGFRB Platelet-derived growthfactor receptor β Upregulated Microarray profiling [44,50]
POSTN Periostin Upregulated Microarrayprofiling, IHC [44]
S100A4
Fibroblast-specific protein 1
(FSP1)/S100 Calcium
Binding Protein A4 (S100A4)
Upregulated Immunofluorescence,RT-qPCR, Western Blot [51–53]
S100A6 S100 Calcium BindingProtein A6 Downregulated
Tag profiling,
IHC, RT-qPCR [38]
SPARC Secreted Protein Acidic andCysteine Rich Up/downregulated
Microarray profiling,
Tag-profiling [38,44]
STC1 Stanniocalcin 1 Downregulated Tag profiling,IHC, RT-qPCR [38]
THY1 Cluster of differentiation 90(CD90) antigen Upregulated IHC [54]
TNC Tenascin C Upregulated RT-qPCR, IHC [42,43]
VIM Vimentin Upregulated IHC [42]
The table reports the main genes coding for cellular or secreted stromal proteins, whose expression differs between
cancer-associated fibroblasts (CAFs) and normal fibroblasts in PCa. Gene expression has been evaluated at the RNA
level (microarray profiling, tag-based RNA profiling, reverse transcription quantitative PCR (RT-qPCR)), and/or
protein level (immunohistochemistry (IHC), Western blot) in the reported publications. Genes upregulated in CAFs
can be considered CAF markers, even though their expression may not be restricted to fibroblasts.
To conclude, the multiple functions exerted by CAFs within the TME make them an attractive
therapeutic target. In this regard, the therapeutic strategies might focus on targeting ECM components,
blocking signaling pathways involved in the crosstalk with cancer cells, or reprogramming CAFs into
normal fibroblasts [24]. Despite their various origins and definitions, CAFs have distinct pro-tumorigenic
properties not shared by fibroblasts and MFBs in a normal tissue context, and thus represent an important
component of tumor biology.
3. CAF Heterogeneity
The advance and application of single-cell analysis technologies is providing increasing evidence that
CAFs do not represent a homogenous cell population within the TME [24]. Prostate CAF heterogeneity
has been observed in terms of expression of distinct markers associated with different CAF functions
(Table 1). For example, cluster of designation antigen 90 (CD90)-high fibroblasts show higher tumorigenic
properties than those that are CD90-low and CD105+ fibroblasts promote neuroendocrine differentiation
of prostate adenocarcinoma [15,55]. CD90 also serves as a quantitative marker for reactive stroma,
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showing increased presence in CAFs and low expression in benign stroma (Table 1) [54]. Another example
of CAF heterogeneity in PCa is the co-existence of CAF subpopulations that are positive/negative for TGFβ
receptor II (TGFβRII), a feature that seems to promote prostate tumorigenesis [56,57]. Recently, single-cell
RNA sequencing of human prostate CAFs has revealed six main CAF subpopulations that secrete
different arrays of cytokines with various immunomodulatory properties [58]. Among these CAF clusters,
the chemokines (C-C motif) ligand 2 (CCL2) and (C-X-C motif) ligand 12 (CXCL12) were found to be
differentially expressed—information that could not be revealed by sequencing the RNA of the bulk
population. These cytokines have different functions, but they both contribute to the generation of an
immunosuppressive microenvironment [58]. Specifically, CCL2-secreting CAFs recruit tumor-associated
macrophages, while CXCL12-secreting CAFs activate other immune components as mast cells, eosinophils,
innate lymphoid cells, and helper T cells [58].
CAF heterogeneity suggests the possibility that CAFs may interconvert, co-evolving with adjacent
PCa cells [24]. Indeed, gene expression analysis of various CAF markers indicates that distinct factors are
expressed according to PCa stage and androgen dependence [59]. In particular, it has been shown that
growth factors such as FGF7 are mostly expressed in fibroblasts from localized tumors, whereas matrix
metalloproteinases (MMPs), as MMP-11, and androgen receptor (AR) are highly expressed in CAFs
from metastatic CRPC [59].
A spatial transcriptomic analysis of different prostate sections from a single prostate containing
multifocal lesions revealed significant spatial heterogeneity in both epithelial and stromal components,
further supporting the existence of multiple CAF subpopulations [60]. The gene expression profile of
stromal cells in the center of the neoplastic lesions was associated with altered metabolism, oxidative
stress, and a hypoxic environment, indicating that in these regions the stroma represents an important
source of energy for cancer cells [60]. By contrast, in regions adjacent to the tumor the expressed genes
were mainly related to stress and inflammation, a characteristic typical of pre-neoplastic lesions [60,61].
To conclude, CAF heterogeneity and, more generally, stromal heterogeneity within prostate TME
may explain the multiple functions played by CAFs in tumorigenesis. Furthermore, heterogeneity of
CAFs over the various stages of tumor progression supports the hypothesis that they co-evolve together
with cancer cells. Additional investigation of the molecular mechanisms of interaction between tumor
and stromal cells is needed to more fully understand CAF functions.
4. Stroma Characteristics in Prostate Homeostasis and Disease
In addition to PCa, stromal modifications of prostate tissue occur in prostatic non-cancerous
lesions such as benign prostatic hyperplasia and prostatic intraepithelial neoplasia. In this section we
describe the characteristics of the stroma in normal prostate and in disease conditions, with a specific
focus on CAFs and ECM components.
4.1. The Stroma in Prostate Homeostasis
Normal prostate tissue has a structured organization consisting of prostatic ducts lined with
epithelial cells surrounded by a fibromuscular stroma (Figure 2) [62–64]. The crosstalk between
epithelial cells and the surrounding stromal components is fundamental in the context of normal
prostate tissue to maintain its homeostasis [1,64]. The epithelium is well-organized and contains
polarized epithelial cells with their apical side facing the lumen of the duct and their basal side
facing the basement membrane [65], a fibrous, thin ECM layer rich in laminin and collagen type-IV
that separates the epithelial cells from the stroma [66]. There are three main types of epithelial cells:
luminal cells, basal cells, and rare neuroendocrine cells [67]. Luminal cells are secretory cells that are
exposed to the lumen of the duct and that express cytokeratins 8 and 18 (CYK8, CYK18), AR (androgen
receptor), NK3 Homeobox 1 (NKX3.1), and prostate specific antigen (PSA) [67,68]. In the absence of
androgens these cells undergo apoptosis, leading to the regression of the prostate tissue [65]. Basal cells
adhere to the basement membrane and are characterized by the expression of p63 and cytokeratins 5
and 14 (CYK5, CYK14), while neuroendocrine cells express chromogranin A, synaptophysin, enolase 2,
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and CD56 [67,68]. The basal and luminal layers have both been found to contain multipotent stem cells
capable of generating basal, luminal, and neuroendocrine cells [69,70].Cancers 2020, 12, 1887 7 of 28 
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Figure 2. Prostate anatomy. Representation of the prostate anatomy oriented in the anterior-posterior
body axis, with the prostatic zones highlighted in different colors. PCa foci mainly occur in the peripheral
zone of the prostate. Representative histology (Hematoxylin and Eosin (H&E) staining) of normal
prostate tissue (left), in which epithelial cells form acinar structures surrounded by a fibromuscular
stroma, and of PCa tissue (right), which shows disruption of the epithelial organization and high
stroma abundance. Scale bars: 50 µm.
The components of the normal prostate stroma are fibroblasts, smooth muscle cells, endothelial
cells, nerve cells, and ECM proteins [63,64]. Fibroblasts are characterized by the expression of the
marker vimentin, whereas smooth muscle cells are marked by the expression of α-SMA and calponin
(Figure 1) [42]. Prostate cell surface profiling identified fibromuscular stromal cell surface markers
including the cluster of designation antigens, CD49a, CD49e, CD51/61, and CD30, that distinguish
fibroblasts from other stromal cell types (endothelial, perineural, nerve sheath cells) [49]. The ECM
forms a dynamic and organized mixture of molecular components, such as collagens, proteoglycans,
thrombospondin, and hyaluronic acid, that respond to tissue injuries and allow its regeneration [32].
Interactions between the epithelium and the basement membrane are fundamental to maintain
epithelial cell polarity and therefore tissue homeostasis [71]. Indeed, disruption of the integrity of
the basement membrane represents a fundamental initiating event in benign prostatic hyperplasia
and prostate carcinogenesis and is a pre-requisite for cancer cell invasion [71]. Interestingly, in the
normal microenvironment, tissue homeostasis is also maintained through reciprocal interactions between
smooth muscle and epithelial cells (Figure 1) that occur in the presence of androgens [72]. Smooth muscle
cells respond to the presence of androgens by releasing factors that maintain the differentiation of
epithelial cells and inhibit their proliferation [72]. Reciprocally, epithelial cells signal to smooth muscle
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cells to maintain their differentiated state. In this context, testosterone is a crucial factor to ensure tissue
homeostasis by maintaining smooth muscle cell differentiation through the activity of transcription
factors such as AR and serum response/myocardin (Srf/Myocd) complex [73,74]. The activity of the T-box
transcription factor 18 (TBX18) and Hedgehog (Hh) signaling are also fundamental for the differentiation
and maintenance of smooth muscle cells [75,76].
4.2. The Stroma in Benign Prostatic Hyperplasia
Alterations of prostate tissue homeostasis may be initiated by the presence of focal prostatic
atrophy or hyperplasia. These types of lesions typically consist of highly proliferative epithelial and
stromal cells, which result in gland enlargement on a background of chronic inflammation [77].
Benign prostatic hyperplasia (BPH) is a non-malignant growth of the prostate, typically occurring
in older men with an occurrence of 80–90% of men in their 70s [78]. The human prostate consists of
an anterior fibromuscular stromal region and three glandular zones: the central zone surrounding
the ejaculatory duct, the transition zone surrounding the urethra, and the peripheral zone (Figure 2),
representing over 70% of the glandular prostate [79]. BPH develops in the transition zone differently
from PCa foci, which usually develop in the peripheral zone. The different localization of these two
events is not yet completely understood, but significant differences in terms of gene expression profiling
have been identified in both epithelial and stromal cells from the peripheral and transition zone of
normal prostate tissue [80,81]. This suggests that different types of epithelial-stromal interactions
might be responsible for the distinct localization of these pathologies.
Smooth-muscle tone is increased in BPH and this is associated with the development of low
urinary tract symptoms that are typical of this pathology [78]. Different molecular players are involved
in the process of smooth muscle cell contraction, such as α1-adrenergic receptors, the Src family kinases,
and the hormone Ghrelin [82–84]. Drugs inhibiting the activity of these elements could be effective for
reducing prostate volume and smooth muscle contractility in BPH, with α1 receptor blockers already
in use on the market [85].
Prostatic epithelium maintains its structural organization in BPH, even if evidence suggests an
increase in its permeability [86]. This is indicated by the presence of PSA in the stromal compartment,
which is secreted by epithelial luminal cells and in physiological conditions does not cross the
epithelial barrier. In BPH, increased epithelial cell proliferation and reduced cell–cell contact, which
might be caused by loss of E-cadherin expression, loose the epithelial cell layer, thus increasing its
permeability [86].
Epithelial cell proliferation results in enlarged nodules, whereas the stromal components show
pro-inflammatory properties [87]. Indeed, with aging, prostate tissue presents a reduced capacity to
regain its homeostasis following tissue injuries or microbial infections, thus increasing the probability
of undergoing a chronic inflammatory state. The stroma of BPH is composed mainly of proliferating
fibroblasts and MFBs characterized by vimentin and α-SMA expression and by smooth muscle cells
expressing calponin and α-SMA [87]. MFBs secrete ECM proteins such as collagen type-I and tenascin
C (TNC), similarly to PCa reactive stroma [87]. TNC is an ECM glycoprotein with many extracellular
binding partners, including matrix components as fibronectin and soluble factors, and its expression in
fibroblasts is stimulated by signaling molecules as TGF-β and tensile strain [88]. It acts as a reservoir
for growth factors and it directly influences cell phenotype through interactions with cell surface
receptors as integrins which promote cell adhesion, migration, and proliferation [88]. TNC deposition
is a hallmark of PCa reactive stroma and is particularly relevant in PCa tumorigenesis, as we will
further discuss [42].
Aging prostate stroma also secretes several inflammatory cytokines, such as CXCL5 and CXCL12,
that drive an increase in the proliferative capacity of epithelial and stromal cells contributing to the
development of BPH [89]. Moreover, interleukin-8 (IL-8) expression correlates with the presence of
MFBs and it can be used as a marker to diagnose BPH [90].
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BPH epithelium retains androgen dependency and thus drugs interfering with androgen activity
can be used as treatment option. For example, 5α-reductase inhibitors block the conversion of
testosterone into dihydrotestosterone, causing a reduction of prostate volume [91]. AR signaling is active
not only in epithelial cells but also in stromal cells, with evidence showing that induction of stromal AR
degradation reduces prostate size in mouse models, which mimics BPH disease [92]. This highlights the
therapeutic potential of targeting AR in both the epithelial and stromal compartments [93]. In addition,
estrogen receptor-α and estrogen receptor-β expression has also been observed in stromal and epithelial
cells, respectively, with significantly higher expression levels in BPH versus normal prostate [94].
Estrogens mediate a paracrine communication between epithelial and stromal cells, which may either
promote or inhibit cell proliferation, suggesting that selective estrogen receptor modulators might be
used as therapeutic agents [91].
In conclusion, BPH stroma is characterized by features typical of fibrotic diseases and reactive
stroma, such as exacerbated inflammation, altered ECM composition, and the presence of MFBs, yet it
is pathologically distinct from PCa, being considered a benign enlargement of the prostatic gland due
to aging prostate physiology.
4.3. The Stroma in Pre-Neoplastic Lesions
Focal atrophic lesions, characterized by chronic inflammation, can occur in all areas of the prostate,
with a special preference for the peripheral zone [61]. Some of these lesions are often characterized by an
increase in cellular proliferation [95] that could result from epithelial damage. These types of lesion are
termed proliferative inflammatory atrophies (PIA). In line with what was discussed previously, PIA lesions
occurring in the transition zone of the prostate could be the basis for BPH development, given the
fact that this pathology is characterized by chronic inflammation [61]. PIA lesions in the peripheral
zone could instead be precursors of prostatic intraepithelial neoplasia (PIN), which subsequently may
progress into invasive prostate adenocarcinoma [61,77]. Multiple causes, such as infectious agents,
cell injury (e.g., exposure to chemicals), hormonal alterations, type of diet, and urinary retention,
underlay the development of PIA lesions [61]. These inflammatory events initiate a series of stromal
transformations that increase oxidative stress, generating the conditions for initiating a tumorigenic
process. Macrophages infiltrate the injured tissue releasing reactive oxygen species (ROS) and reactive
nitrogen species that cause genomic instability and alterations in gene expression, thus activating a
vicious cycle that opens the route to cancer progression [61,63]. Alterations in AR gene repeat lengths,
downregulation of CDKN1B tumor-suppressor gene (coding for p27) and hypermethylation of glutathione
S-transferase P (GSTP1) gene (coding for an enzyme that reduces oxidative stress) have been observed in
PIA lesions, supporting this hypothesis [61].
Due to chronic inflammation and oxidative stress, PIA foci, mainly in the peripheral zone of the
prostate, may progress into PIN [61,77]. PIN is characterized by proliferating atypical epithelial cells
within the prostatic duct with visible prominent nucleoli in high-grade PIN [96]. High-grade PIN is
considered to be the preliminary stage of invasive prostate adenocarcinoma, supported by the fact
that in both cases similar genetic alterations have been observed and that in prostatectomy specimens
PIN is usually closely associated with the neoplastic lesion [96,97]. In contrast to PCa, high-grade PIN
retains the basal cell layer (Figure 1), although it is fragmented [98].
The presence of MFBs has been observed among periacinar fibroblasts adjacent to PIN foci,
characterized by increased vimentin staining and α-SMA expression [42]. Furthermore, it has also
been demonstrated that prostate epithelial cells in PIN lesions, as well as in malignant lesions,
produce kallikrein-related peptidase-4 (KLK4), which induces normal fibroblasts to acquire the CAF
phenotype (Figure 1) [99]. In this context, CAFs become more proliferative and start to secrete a series
of pro-tumorigenic and pro-angiogenic cytokines, such as IL-8, VEGF, and FGF1 (Figure 1) [99]. In a
mouse genetic model, PI3K alpha catalytic subunit overexpression in prostate epithelial cells led to
widespread PIN development with few invasive cells [100]. Despite the presence of low-tumorigenic
lesions, prostate stroma was heavily modified showing typical features of PCa reactive stroma:
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increased collagen deposition and high stromal cell levels of the phosphorylated signal transducer
SMAD2, indicating enhanced TGF-β signaling activity [100]. This indicates that PI3K overexpression
in epithelial cells may induce release of TGF-β ligands, which act on stromal cells, inducing MFB
transition and increased collagen deposition (Figure 1) [42,100]. Altogether, these results suggest that
the stromal component of the prostate tissue is profoundly modified already with the occurrence of
high-grade PIN, generating a suitable TME to allow progression toward invasive PCa.
In conclusion, high-grade PIN is nowadays the only recognized precursor of prostate adenocarcinoma.
Nevertheless, the presence of chronic inflammatory states such as PIA lesions, especially in the peripheral
zone of the prostate, could also be a relevant indicator of a potential progression into PCa [61,77].
4.4. The Reactive Stroma in Prostate Cancer
PIN lesions progress into prostate adenocarcinoma when epithelial cells from PIN foci develop
genetic alterations and acquire an invasive phenotype. In high-grade PIN, loss of β4-integrin or
laminin-332 expression in basal cells induces a discontinuous basement membrane, resulting in
gaps that allow prostate epithelial cells to enter the surrounding stroma (Figure 1), disrupting the
typical acinar structure of prostate epithelium and inducing stroma remodeling (reactive stroma) [101].
Such mechanisms are likely to be at the basis of high-grade PIN progression into adenocarcinoma.
Increasing evidence has demonstrated the tumorigenic contribution of CAFs, which represent the
most abundant stromal component in PCa [64]. By using both in vitro and in vivo systems, it has been
shown that human CAFs derived from PCa are able to enhance the growth and tumorigenicity of BPH-1
and LNCaP prostate epithelial cells, in contrast to normal fibroblasts [19,102,103]. However, PCa stromal
cells do not generally harbor somatic genomic mutations [104]. These observations suggest that normal
prostatic fibroblasts and CAFs establish distinct types of paracrine communication with epithelial tumor
cells, and that PCa influences the activity of the stroma through epigenetic or transcriptomic mechanisms
to generate a tumor-supporting environment [2].
Immunohistochemical characterization of samples from normal, PIN, and PCa tissues revealed
the main feature of PCa reactive stroma (Figure 2), elucidating pro-tumorigenic properties of CAFs and
ECM [42]. Compared to normal prostate stroma, the reactive stroma has a lower number of smooth
muscle cells, identified by co-expression of α-SMA and calponin (Figure 1), and a high number of
CAFs (Figure 1), which show either a ‘fibroblast-like’ or ‘MFB-like’ phenotype. ‘Fibroblast-like’ CAFs
are identified by vimentin and FSP-1 expression, whereas ‘MFB-like CAFs’ co-express vimentin and
α-SMA [37,42]. MFBs may originate from pre-existing fibroblasts, because the secretion of TGF-β by
PCa epithelial cells is able to induce this transition (Figure 1) [42]. CAFs are also characterized by high
expression of genes including FAP, PDGFRB, TNC, ASPN, and POSTN, among others, which contrasts
with normal prostate fibroblasts (Figure 1, Table 1) [38].
Furthermore, CAFs induce high collagen-I and TNC deposition (Figure 1), typical hallmarks of
reactive stroma, and express fibroblast activating protein (FAP) [42], a cell-surface bound protease that
is able to induce the degradation of collagen-I, contributing to matrix remodeling [105]. In addition,
laminin expression is reduced in the reactive stroma indicating disruption of the basement membrane [106].
Subsequent studies have given evidence of the pro-angiogenic and immunomodulatory properties of
CAFs in prostate carcinogenesis [58,107]. Overall, the properties of CAFs and ECM components in prostate
reactive stroma support the aforementioned idea that tumors behave as ‘wounds that do not heal’.
It has also been shown that fibroblasts from different zones of the prostate have a different influence
not only on primary PCa tumorigenesis, but also on metastatic development [19]. Fibroblasts from
peripheral and transition zones, in contrast to central zone fibroblasts, alter the cytogenetic profile
and stimulate the tumorigenicity of LNCaP cells in vivo [19]. Indeed, peripheral and transition zone
fibroblasts were able to promote androgen-independent tumor growth of androgen sensitive prostate
adenocarcinoma LNCaP cells in castrated mice, and even metastasis formation in lymph nodes, bone,
and lung [19]. This result supports a role for CAFs in the development of CRPC, suggesting that novel
therapeutic strategies targeting CAFs should be used in combination with ADT.
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Due to the impact of prostate TME on cancer progression, characterization of stromal components
and gene expression profile analysis can be used to identify prognostic or predictive biomarkers.
For example, low expression of desmin, an intermediate filament protein typical of differentiated smooth
muscle cells [25], and α-SMA is associated with shorter biochemical recurrence (BCR)-free survival [16].
In addition, a high stromal gene expression score in primary PCa (determined on the expression of
stromal infiltration markers) correlates with high genomic risk scores and metastatic progression [108].
Stromal cell infiltration correlates with decreased DNA repair gene expression, but also with better
sensitivity to radiation therapies [108]. Whole genome and whole exome sequencing analysis on
PCa patient-derived xenografts has identified a 93-gene stroma-derived metastatic signature that can
independently predict metastatic progression even in intermediate-risk primary PCa patients [109].
A combination of metabolic and transcriptomic profiling was performed in histologically defined PCa
tissues with low versus high reactive stroma content [110]. High reactive stroma tissues were enriched
in metabolites and transcript expression was linked to ECM and immune pathways, and there was
also a significant association with BCR progression [110]. Finally, analysis of the amount of reactive
stroma fraction together with PCa cells DNA ploidy represents a prognostic tool to predict disease
recurrence [111].
5. Tumor–CAF Interactions in Primary Prostate Cancer
In this section, we discuss the multiple ways in which CAFs affect the primary PCa microenvironment
and tumor growth, particularly regarding ECM modulation, signaling interaction mechanisms with
tumor cells and androgen regulation. Different methods have been implemented for the study of prostate
epithelial-stromal interactions, such as the in vivo smooth muscle invasion xenograft model to assess
the invasive potential of human tumor cells into the smooth muscle/skeletal muscle structures of the
diaphragm [112], the differential reactive stroma xenograft model [107], the 3D co-culture of organoids
with prostate stromal cells [113], and the novel microfluidic human prostate in a chip ex vivo model [114].
5.1. ECM Remodeling by CAFs
In contrast to normal fibroblasts, CAFs overproduce various ECM components, such as collagens,
TNC, hyaluronate, and fibronectin (Figure 1) [42,115–117], resulting in biochemical signaling alterations
and increased matrix stiffening, which promotes tumor growth and invasion [32]. A high deposition
of various collagen types, such as collagen type-I and -III, increases matrix stiffness, promoting PCa
cell migration, invasion, and eventually metastasis [115]. Interestingly, fibronectin produced by CAFs
forms an oriented network of fibers that interacts with PCa cells through integrin-αv to establish routes
for PCa cell migration [117].
In a recent study, proteomic analysis of CAFs from PCa patients and matched normal fibroblasts
has shown that the CAF proteome is enriched for the ‘cell adhesion’ and ‘extracellular matrix’
functional categories [118]. Protein interaction analysis highlighted multiple proteins involved in
collagen synthesis, modification, and signaling as the collagen types COL1A1/2 and COL5A1, discoidin
domain-containing receptor 2 (DDR2) collagen receptor, and lysyl oxidase-like 2 (LOXL2), an enzyme
involved in collagen crosslinking [118]. These data support the hypothesis that CAFs actively modify
the ECM composition of the reactive stroma, generating a tumor-supportive microenvironment.
Expression of matrix proteases such as FAP and MMPs also contributes to CAF-mediated ECM
remodeling [24]. MMPs are secreted by both cancer cells and CAFs [119], and their activity of
hydrolyzing ECM components is controlled by tissue inhibitors of matrix metalloproteinases (TIMPs),
which are also secreted by both epithelial and stromal cells [120]. In PCa, an imbalance between MMPs
and TIMPs leads to a general upregulation of MMPs and reduced expression of TIMPs, and enhances
PCa cell invasiveness [120,121]. A possible mechanism explaining the increased expression of MMPs is
loss of Dickkopf-3 (DKK3) expression in both prostate epithelial and stromal cells. DKK3 is a secreted
protein that inhibits TGFβ signaling activity and DKK3 silencing is associated with an increase of
MMP-2 and MMP-9 secretion [122,123]. Increased MMP activity not only affects tumor invasiveness,
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but also influences other aspects of tumorigenesis such as cell proliferation, apoptosis, angiogenesis,
and EMT (Figure 1) [119,120]. Moreover, higher serum levels of MMPs and lower levels of TIMPs are
correlated with disease progression in PCa patients [120]. Finally, protease-mediated matrix degradation
determines the release of previously ECM-bound growth factors with tumorigenic properties such as
TGF-β, FGFs, and HGF [32].
5.2. CAF-Tumor Signaling: Paracrine, Systemic, Cell–Cell Direct, and Metabolic
CAFs and cancer cells interact with each other through the secretion of soluble factors to establish a
network of paracrine communication that sustains tumor growth. Among the secreted signaling molecules,
TGFβ certainly has a dominant role in the regulation of TME biology, inducing fibroblasts to acquire a
CAF phenotype. PCa cells release TGFβ to induce normal fibroblasts-to-MFBs transition and stimulate
TNC deposition (Figure 1) [42]. This TGFβ-mediated effect on CAFs is further increased after castration,
suggesting that stromal remodeling underlies the development of CRPC [65]. TGFβ released from PCa
cells also determines NADPH-oxidase 4 (Nox4) expression in CAFs (Figure 1), which induces metabolic
changes characterized by high ROS production [124]. CAF-derived ROS, in turn, enhance tumor cell
proliferation and migration. In PCa reactive stroma, loss of TGFβ signaling activity in subgroups of
CAFs has been identified [56,57]. In vitro and in vivo experiments showed that a mixture of fibroblast
populations positive and negative for TGFβRII induced malignant transformation of non-tumorigenic
prostate cells, similarly to CAFs, whereas this effect was not seen with the single populations [56,57].
The co-culture of the two fibroblast types enhanced the production of pro-tumorigenic factors TGFβ1,
CXCL12, and FGFs [56,57]. These observations reveal the complexity of TGFβ-mediated signaling in
prostate TME. Further investigations are needed to dissect these signaling interactions and to target TGFβ
signaling for therapeutic purposes.
IL-6, which is produced by both PCa and stromal cells, is another fundamental player within the
PCa microenvironment that influences many aspects of prostate tumorigenesis, including proliferation,
angiogenesis, and insensitivity to androgens [40,125,126]. For example, CAF-secreted IL-6 induces
VEGF secretion from PCa cells, stimulating tumor angiogenesis (Figure 1) [40]. Due to its multiple
effects on prostate TME, the clinical use of inhibitors of IL-6 or its related transcription factor STAT3 is
under investigation [126]. Other examples of molecular players involved in paracrine communication
between cancer cells and CAFs are secreted frizzled-related protein 1 (SFRP1), FGF2, FGF10, heat shock
protein 90 (HSP90), YAP signaling and Hedgehog (Hh) signaling components (Figure 1) [47,48,127–130].
Extracellular vesicles have been found to play a relevant role in the paracrine communication
between cancer cells and CAFs in prostate TME, acting as transporters of cellular DNA, RNA,
and proteins [131]. PCa cells release exosomes that contain TGFβ1, which induces MFB transition
(Figure 1) [132]. By disrupting the exosome secretion process in PCa cells, the stroma loses its
growth-promoting properties [132]. In addition, CAFs secrete exosomes containing non-coding RNAs,
such as microRNA-409, which inhibits the translation of tumor-suppressor genes, promoting EMT and
thus tumor invasiveness (Figure 1) [133].
Factors secreted by CAFs might also have a systemic/endocrine effect on the organism. A study
suggests that the TGF-β/BMP family member GDF15, secreted by CAFs, exerts not only a paracrine
effect on tumor growth, migration, and invasion (Figure 1), but also has tumor-instigating properties on
distant PCa cells [41]. Indeed, by using a xenograft model the authors showed that GDF15-expressing
fibroblasts induce the outgrowth of PCa cells implanted in a distinct site in a manner that is distinct
from control fibroblasts [41]. Supporting its systemic effect, high serum GDF15 levels are correlated
with weight loss and anorexia in advanced PCa patients and in PCa xenograft models [134].
PCa cells and CAFs can establish signaling interactions through direct cell–cell contact. Physical
interaction between the two types of cells is relevant for the regulation of cancer cell motility through
modulation of Eph-Ephrin signaling (Figure 1) [135]. A study using in vitro co-cultures of PC-3 prostate
cancer cells and fibroblasts demonstrated that the transmembrane EphrinB2 ligand interacts with
its receptor EphB3/4 in PC-3 cells activating Cdc42 signaling, which stimulates cancer cell migration
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and causes a failure of contact inhibition of locomotion [135]. This study suggests that direct contact
between CAFs and cancer cells promotes PCa invasiveness and this hypothesis is supported by
the high expression in advanced human PCa of EphB3/4 and EphrinB2 in epithelial and stromal
cells, respectively [135]. Another study suggests that direct cancer–stromal cell contact enhances the
tumorigenic properties of the reactive stroma by activating Notch signaling in stromal cells through
the interaction between Jagged1 ligand, bound to PCa cell membranes, and its cognate receptors on
CAFs [136]. This causes the formation of inflammatory foci and activates TGFβ signaling in stromal
cells, thus promoting tumor progression.
Interestingly, CAFs can also support PCa cell oxidative metabolism by releasing lactate and
forming cellular bridges to transfer their mitochondria to cancer cells, as it has been shown in both
in vitro and in vivo PCa models [137]. Mitochondrial metabolism promotes cell proliferation and
inhibits apoptosis. Its activation is related to the reverse Warburg effect, a phenomenon observed in
many cancer types including PCa, in which CAFs undergo aerobic glycolysis to release pyruvate and
lactate that are used by cancer cells to activate mitochondrial oxidative metabolism [138]. The fact that
CAFs and PCa cells establish cellular bridges to transfer mitochondria indicates that these tumors
strongly depend on the stroma to sustain their metabolism and growth.
5.3. CAF-Mediated Resistance to Androgen Deprivation and Chemotherapy
It is largely recognized that androgens mediate their pro-tumorigenic effects by binding AR
in PCa epithelial cells, inducing its nuclear translocation and transcriptional activity. In addition,
AR transcriptional activity in PCa cells may become androgen-independent following ADT leading to
CRPC [139]. Increasing evidence supports the idea that CAFs are also sensitive to changes in tumor
androgen levels, mediating the development of resistance to anti-androgen therapies. Indeed, AR signaling
is active in CAFs, similarly to smooth muscle cells and fibroblasts in the normal prostate stroma and BPH,
as well as in other stroma components (endothelial, immune cells) [140]. Chromatin immunoprecipitation
sequencing (ChIP-seq) analysis in CAFs and PCa cells has demonstrated that upon testosterone exposure,
AR in CAFs interacts with different genomic sites than in PCa cells, thus having distinct genomic targets
in different cell types. AR in CAFs activates a signaling network which suppresses the expression of
inflammatory cytokines, such as CCL2 and CXCL8, which have tumor-promoting properties [141].
Consequently, reduced AR signaling activity following ADT increases CAF-mediated secretion of
these cytokines, enhancing PCa cell motility [141]. This is in line with the fact that decreased stromal
AR expression in PCa is associated with earlier disease progression and BCR, thus suggesting an
antitumorigenic role of stromal AR during the early, hormone-naïve stages of PCa [142–144].
Several studies indicate that CAFs also actively promote PCa resistance to anti-androgen therapies,
thus inducing CRPC. CAF-derived IL-6 is involved in this process, with evidence suggesting that it
could enable AR transcriptional activity in PCa cells in the absence of androgens by modulating MAPK,
STAT3, and PI3K/AKT signaling [40,125]. In 3D co-culture models of CAFs/PCa cell lines, CAFs decrease
the sensitivity to the anti-androgens bicalutamide and enzalutamide in a PI3K/Akt signaling-dependent
manner [14]. In this regard, it was hypothesized that the presence of CAFs might reduce drug
accessibility, especially to the central part of the tumor [14]. A possible involvement of CAFs in the
progression towards neuroendocrine CRPC has also been reported [15,145]. For example, ADT induces
the expansion of a specific CD105+ subpopulation of CAFs, which releases secreted frizzled-related
protein 1 (SFRP1), a mediator of Wnt signaling, promoting neuroendocrine differentiation of the
adjacent epithelial cells [15]. Androgen depletion also leads to CAF epigenetic silencing of the RASAL3
gene, coding for a Ras inhibitor [145]. Activation of Ras signaling induces CAFs to produce and release
glutamine, which is taken up by PCa cells and activates mTOR signaling favoring neuroendocrine
differentiation of prostate adenocarcinoma cells [145].
In addition to counteracting the effect of ADTs, CAFs also inhibit the effectiveness of general
chemotherapies. For example, they mediate resistance to cytotoxic agents, such as docetaxel, through the
expression of a spectrum of genes, including the NF-κB-dependent expression of the Wnt family
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member WNT16B, which promotes EMT in PCa cells [39]. CAFs also cause resistance to genotoxic
agents such as doxorubicin by releasing glutathione, which reduces ROS levels and prevents drug
accumulation in cancer cells, possibly by increasing cellular drug efflux and/or decreasing drug
influx [146]. Relapse following androgen ablation or chemotherapy can be linked to high levels of the
chemokine CXCL13 and the resulting recruitment of B cells, which indicates poor patient prognosis
(tumor recurrence or metastasis) [147]. CAFs are the source of CXCL13, the secretion of which occurs
via a mechanism involving intra-tumoral hypoxia and TGFβ signaling. Pharmacologic inhibition of
CXCL13 and MFB/CAF depletion both prevent CRPC progression in vivo [147].
Altogether, these results indicate that not only epithelial cells, but also CAFs, are sensitive to
changes in androgen levels. Therefore, to overcome therapy resistance, combinatorial therapies taking
into account the response of stromal cells to anti-androgens as well as chemotherapeutics are needed.
6. Stroma in PCa Bone Metastasis
Metastasis requires multiple steps to occur: primary PCa cells that have acquired migratory
capacity first invade blood vessels (usually following EMT), then they enter and survive in the
circulation, and finally they extravasate and start to proliferate in a secondary metastatic site [22,23].
This is a very inefficient process with only around 0.01% of circulating tumor cells succeeding [23].
In this context, interactions between cancer cells and the new metastatic microenvironment are
fundamental [22]. Circulating tumor cells need to acquire characteristics that allow their survival in
the circulation and growth in the new metastatic environment, which is different from the primary
TME. In addition, they develop a tropism for specific organ sites with the optimum conditions for their
survival and growth. As Paget’s paradigm suggests, both the tumor and its suitable microenvironment,
the ‘seed’ and the ‘soil’, need to develop features to initiate a paracrine communication promoting the
metastatic outgrowth [148].
Prostate adenocarcinoma predominantly forms bone metastases [20]. A possible determinant
of PCa bone tropism is chemokine (C-X-C motif) receptor type-4 (CXCR4)/chemokine (C-X-C motif)
ligand 12 (CXCL12) signaling [149]. Bone stromal cells such as osteoblasts and endothelial cells release
CXCL12 ligand, generating a gradient that attracts PCa circulating cells expressing the CXCR4 receptor
towards the bone marrow (Figure 3A), as has been demonstrated in mouse models [150]. This molecular
mechanism of recruitment is also responsible for the homing of hematopoietic stem cells (HSCs) in
the bone marrow. Indeed, it has been shown that PCa cells co-localize and compete with HSCs for
HSC-niche occupancy (Figure 3A), suggesting that it may represent a favorable microenvironment for
their metastatic growth [151]. Once PCa cells reach the metastatic site, they adhere to the endothelial
monolayer and then to collagen, fibronectin, and laminin fibers within the bone, by anchoring through
integrins (Figure 3A) including α5β3 and α2β1 [150,152]. Adherence of PCa cells is selective to
different matrix substrates that contain collagen, laminin, and/or fibronectin. Interaction between
CD49b/CD29 (α2β1) integrin and collagen type-I induces cytoskeletal rearrangements in the metastatic
cells enhancing migration and invasiveness [152]. PCa cells show preferential adhesion to collagen,
since they express α2β1 integrin, whereas adherence to laminin is less favorable, since CD49a/CD29
(α1β1) integrin, whose ligand is laminin, is present predominantly on stromal cells rather than tumor
cells [49]. The high collagen levels in the bone matrix and the high PCa adhesion to collagen may
contribute to bone tropism [153].
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(A) Changes occur in PCa cells during bone metastasis (BM) progression. PCa cells undergo EMT to
acquire an invasive phenotype and e r ss receptor to become sensitive to CXCL12 gradient
and migrate towards the bone. They also express integrins to adhere to collagen fibers and enter
the bone-marrow niche, in which they compete with hematopoietic stem cells (HSCs) for niche
occupancy (since HSC homing to the bone marrow niche is also CXCL12-dependent). To modify the
behavior of resident bone cells (mainly osteoblasts and osteoclasts), PCa cells release factors typically
produced by osteoblasts as parathyroid hormone related peptide (PTHrP), endothelin (ET-1), and bone
morphogenetic proteins (BMPs) (osteomimicry). (B) Reactive stroma of primary high-grade tumors
shares similarities with BM stroma, probably because PCa cells acquire osteomimicry already in the
primary tumor, affecting stromal cell behavior. A population of TGFβRII-negative CAFs is found in
both tumor sites, secreting cytokines CXCL1 and CXCL16 that favor PCa cell establishment in the
BM niche. CAFs in both primary PCa and BM also express ASPN, POSTN, and TNC, highlighting
the similarities between the two microenvironments. TNC expression in the BM niche may favor
the adhesion of disseminated PCa cells. Moreover, expression of bone remodeling proteins biglycan
(BGN) and lumican (LUM) is also detected in primary PCa stroma of high-grade tumors compared to
low-grade or benign stroma.
In bone physiological conditions, a balance between the activity of osteoblasts, which promote bone
mineralization and bone formation, and osteoclasts, which promote bone resorption, maintains tissue
homeostasis. PCa cells alter this equilibrium by expressing genes typical of osteoblasts, a process
called ‘osteomimicry’ (Figure 3A), and thereby interfere with normal bone cell activity [154]. PCa cell
interaction with bone-resident cells causes either excessive bone resorption (osteolytic lesions) or
excessive bo e formation (osteoblastic lesions) [23,155]. Osteolytic lesions are more common in breast
cancer, while th y are less frequent in PCa [23,156], and are charact rized by increased osteoclast a tivity,
which causes bone resorption, leaving free space for cancer cell prolif ration [23]. Osteoblastic lesions
are typical of PCa and are charact rized by increased os eoblast activity, which induces bone deposition
with the generation of woven bone, leading to a higher risk of fractures [23]. However, even in
osteoblastic lesions, there is an initial phase in which bone resorption takes place to allow PCa cell
infiltration [23,156]. This imbalance in the bone remodeling processes may increase the accessibility of
collagen fibers, abundant in the bone matrix [153], facilitating PCa cell adhesion to collagen proteins.
In osteolytic metastasis, the arriving circulating tumor cells promote osteoclast maturation due
to their ‘osteomimetic’ properties. These tumor cells secrete parathyroid hormone-related peptide
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(PTHrP) which induces the expression of receptor activator of nuclear factor-κB (NF-κB) ligand
(RANKL) in osteoblasts that in turn binds the RANK receptor in osteoclast progenitors, mediating
their maturation [23,157]. Cancer cells may also directly stimulate osteoclast maturation through the
release of cytokines such as TNFα, IL-1β, IL-6, and IL-8 [23]. Osteoclast-induced bone resorption
causes the release of calcium and ECM-bound growth factors, including PDGFs, TGFβ, insulin-like
growth factors (IGFs), and bone morphogenetic proteins (BMPs) that stimulate cancer cell proliferation,
completing the so called ‘vicious cycle’ [23,155,157]. The release of growth factors may also ‘awake’
potential dormant cancer cells [158].
In osteoblastic lesions, the arriving circulating tumor cells secrete factors such as endothelin-1
(ET-1), Wnt ligands, IGF-1, and BMPs that induce osteoblast differentiation and proliferation [23,155].
Osteoblasts in turn produce growth factors to sustain the metastatic process [155,156]. Moreover, both cancer
cells and osteoblasts release osteoprotegerin (OPG), a decoy receptor which binds RANKL and thus inhibits
osteoclast maturation [23]. Interestingly, OPG also acts as a decoy receptor for tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL), preventing TRAIL-mediated apoptosis in osteoblastic PCa cells [159].
Finally, evidence show that cancer cells may actively predispose the formation of a favorable
‘pre-metastatic niche’ before their arrival. This phenomenon has been more extensively studied in
other types of solid cancers such as pancreatic and breast cancer, in which the release of exosomes
expressing specific integrin patterns predispose the formation of a suitable microenvironment and
determine organ tropism [160]. However, similar mechanisms have been observed for PCa, since cancer
cells release extracellular vesicles, transporting key molecules including the transcription factor Ets1,
which are thought to promote osteoblast differentiation, inhibit osteoclast maturation, and induce
prostate-specific gene expression in human bone marrow cells [161–163]. Altogether, these findings
highlight that metastasis occurrence requires reciprocal changes of both PCa and bone resident stromal
cells for the formation of a bone-metastatic niche that sustains tumor cell growth.
Role of CAFs in PCa Bone Metastasis
Gene expression studies elucidating the functions and characteristics of bone metastasis stroma
(e.g., in bulk tumor clinical samples) have been hampered by the lack of experimental and bioinformatics
tools to discriminate the tumor from the stromal cells. Much of our knowledge derives from microarray
analysis on laser capture microdissected tumor and stromal areas [164,165] and xenograft models [44],
which allow distinction of the stroma, provided by the host organism, from the human tumor cells.
Nevertheless, the recent development of techniques such as next generation sequencing and single
cell-analysis is changing our understanding of the landscape of PCa reactive stroma in bone metastasis,
as well as in primary PCa, in terms of the multi-omic molecular profiling and elucidation of cellular
processes occurring in distinct stromal cell populations [58,60,166].
By exploiting xenograft mouse models of osteoblastic VCaP and C4-2B PCa cell lines and analyzing
the host tumor stroma via microarray gene expression profiling, a specific PCa osteoblastic bone
metastasis-associated stroma transcriptome (OB-BMST) was generated [44]. Several genes of the
OB-BMST are associated with a previously identified MFB signature [167] and are CAF markers
(Pdgfrb, Sparc) or CAF-recruiting factors (Tgfβ1, Tgfβ3, Fgf2) [44]. Among the most highly expressed
genes, a ‘seven-gene signature’ was identified, not only in the intraosseous xenografts, but also in the
stroma of intraprostatic and ectopic VCaP and C4-2B xenografts, and of subcutaneous patient-derived
xenografts [44,168]. This suggests that the osteoblastic stromal signature is, to some extent, conserved
and thus represents a specific response to the osteoblastic phenotype of these tumor cells. The seven-gene
signature includes periostin (Postn), asporin (Aspn), SPARC-like 1 (Sparcl1), melanoma cell adhesion
molecule (Mcam), platelet-derived growth factor receptor beta (Pdgfrb), fascin homolog 1 (Fscn1) and
prostate transmembrane protein androgen induced 1 (Pmepa1). Among these genes, ASPN and POSTN
expression has been observed also in CAFs from human bone metastatic and primary PCa (Figure 3B),
highlighting the translational and prognostic value of these genes [44]. In contrast, the stromal
signature of osteolytic PCa metastasis (PC-3 cell xenografts) is uniquely enriched in genes involved in
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vascular/axon guidance [169]. Distinct vessel morphology and the presence of vascular smooth muscle
cells and mesenchymal stem cells expressing bone osteolytic factors indicate the requirement for a
different metastatic niche compared to the osteoblastic stroma signature [169]. However, even in this
context CAFs may play a relevant role, since intracardial inoculation of osteolytic PC-3 cells secreting
IL-1β induces FSP-1 expression, a typical CAF marker, in mouse bone stromal cells [53]. Blockade of
IL-1β activity reduces the number of metastatic lesions, suggesting an important pro-tumorigenic role
of skeletal CAFs [53].
Moreover, CAF activity in the bone metastatic niche is likely to be interconnected with osteoblasts
since both are cells of mesenchymal origin and express similar markers and produce bone ECM
components [24,44].
CAFs in bone metastasis may be involved in fibronectin and collagen deposition, establishing an
extensive network of protein interactions within the bone metastatic niche [44]. CAFs also mediate TNC
deposition, as in the primary tumor stroma (Figure 3B). TNC is normally expressed in developing bone
and is absent in adult bone, even though it can be re-expressed during bone regeneration following
fractures [170]. TNC re-expression may also take place during PCa bone metastasis, since it has been
shown that bone metastatic PCa cells interact with TNC through α9β1 integrin when cultured in
osteomimetic surfaces containing this glycoprotein [170]. In addition, in a multi-omics approach study,
TNC protein was detected in the circulation prior to radical prostatectomy and its combination with
three other serum markers and metabolites could predict BCR-free survival with high accuracy [171].
Re-expression of TNC in the bone could be a factor attracting disseminated PCa cells in this site,
supporting the idea that cancer cells tend to metastasize in microenvironments similar to the primary
tumor. Moreover, a gene expression analysis of the stroma of bone metastasis patient-derived xenograft
models suggests that stromal TNC expression is modulated by the presence/absence of androgens [168].
TGFβRII-negative CAF subpopulations have been observed in both primary PCa and matched
bone metastatic human tissue samples [172]. TGFβRII-negative CAFs in primary PCa secrete cytokines
such as CXCL1 and CXCL16 (Figure 3B) which may promote disseminated PCa cell adhesion to bone
collagen-I fibers, leading to the development of mixed osteoblastic/osteolytic lesions [172]. A similar
role of CAFs has also been reported for breast cancer bone metastasis, in which primary tumor
CAFs secrete cytokines (e.g., CXCL12, IGF1) that are highly expressed in bone tissue to generate
a similar microenvironment. In this way, a subset of primary breast cancer cells that has been
“primed” by osteomimetic stromal signals undergoes selection for the ability to colonize the bone
microenvironment [173].
In line with these observations, the OB-BMST signature is partially found in primary breast
cancer and PCa, tumors suggesting the possibility of bone metastasis prediction based on stromal
marker signatures on the primary tumor site [44]. Such ‘stroma osteotropism’ phenomenon could
be explained as a secondary effect induced by the PCa cells, which upregulate osteoblast markers
prior to metastasis (osteomimicry). Large-scale expression profiling of primary PCa tumors with
follow-up clinical information has in fact revealed that high expression of stroma infiltration markers
correlated with a higher risk of metastasis [108], highlighting the prognostic value of the primary stroma.
Characterization of CAF subpopulations, based on multiple marker detection (α-SMA, caveolin-1,
vimentin) by multiplex immunohistochemistry on primary PCa tissue microarray, indicated that
high fibroblast infiltration significantly correlates to CRPC progression and PCa-related mortality,
as assessed independently in two clinical cohorts [174]. Furthermore, transcriptional analysis on
laser-capture microdissected stromal areas in radical prostatectomy tumors, identified an enrichment
for bone remodeling components, such as biglycan (BGN) and lumican (LUM), in stroma adjacent
to high-grade PCa (Figure 3B) compared to benign and low-grade tumors [175]. Given that high
grade adenocarcinomas are more likely to induce bone metastases, this further indicates that the
primary PCa stroma may induce local premetastatic signals to prime tumor cells for metastatic growth
specifically in the bone [173]. Interestingly, it has been speculated that stromal alterations may not
only predict bone metastasis but even precede epithelial cell transformation in primary PCa [175].
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Evidence from expression profiling of benign stromal areas in radical prostatectomy tissues containing
the primary tumor, show that they significantly differ from the stromal profile of a completely normal
prostate [175]. On the contrary, epithelial cells in benign areas from prostates with carcinoma have
similar transcriptomic profile with epithelial areas from non-carcinoma containing prostate tissues.
Thus, the overall stroma of primary PCa is altered, even in areas that are not directly tumor-adjacent
suggesting that paracrine signaling from areas of carcinoma predispose the stroma of non-carcinoma
regions prior to neoplastic transformation of the adjacent epithelial cells. Such studies investigating
the stroma and CAF properties in both primary and metastatic PCa in preclinical models as well as
clinical cases have greatly contributed to understanding new aspects of CAF biology.
To conclude, the role of fibroblasts/CAFs in PCa bone metastasis has not been extensively
characterized yet, as major focus has been given to osteoblasts as the main resident bone stromal cell.
Discrimination of CAF and osteoblast functions, as well as primary and bone CAFs in both osteoblastic
and osteolytic metastatic niches, would elucidate the tumor-supporting mechanisms of prostate stroma,
providing a fundamental contribution for the development of prognostic and therapeutic strategies.
7. Conclusions and Future Directions
Primary, organ-confined PCa is amenable to curative treatments, including surgery, ADT, radiation,
and active surveillance. However, a fraction of patients will manifest metastatic, aggressive disease with
median survival of less than five years. The main unresolved issue of PCa is the lack of prognostic tools
that can identify patients who are at risk for lethal metastatic PCa, as well as a lack of curative treatments
for such patients. The stromal component, as the holder of prognostic information for metastatic
disease progression, has not been particularly investigated, as most work has rather focused on the
characteristics of tumor cells. Studies of previous decades have proven that the stroma, and especially
CAFs, which are the most abundant cell type of TME, are active players in tumorigenesis at the primary
tumor stage. However, the contribution of the stroma and CAFs to the metastatic transition and the
acquisition of androgen resistance and therapy outcomes have not been studied extensively. Could the
specific profile of the stroma be indicative of the presence of an aggressive tumor and be detectable
during therapy resistance or prior to metastasis? To understand how the stroma of the primary tumor
differs during disease stages and from the metastasis stroma, further studies are required, particularly
on matched patient cases. The use of computational tools and advanced methodologies that have only
recently become available, such as whole exome sequencing, single-cell RNA-Seq, and metabolomic
and proteomic methods, has made it possible to identify stromal components that are associated with
disease severity, and may predict disease progression. A unified consolidation of these methods and
validation of different experimental models and clinical cohorts is required. Thus, stroma could be a
contributing factor for discriminating indolent, localized PCa from the aggressive, metastatic form.
The combination of high-throughput molecular analysis of the CAF and stromal compartments,
along with histopathological analysis, should supplement the current diagnostic and prognostic
methods in order to improve prediction models for patient stratification.
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Abbreviations
List of Abbreviations: Full Name:
α-SMA α- smooth muscle actin
ADT Androgen-deprivation therapy
AR Androgen Receptor
ASPN Asporin
BCR Biochemical recurrence
BM Bone metastasis
BMPs Bone morphogenetic proteins
BPH Benign prostatic hyperplasia
CAFs Cancer-associated fibroblasts
CD Cluster of designation antigens
CRPC Castration-resistant prostate cancer
CXCL Chemokine (C-X-C motif) ligand
CXCR Chemokine (C-X-C motif) receptor
ECM Extracellular matrix
EMT Epithelial to mesenchymal transition
EVs Extracellular vesicles
FAP Fibroblast activation protein
FGFs Fibroblast growth factors
FSP-1 (also known as S100A4) Fibroblast-specific protein-1
GDF15 Growth differentiation factor 15
HGF Hepatocyte growth factor
HSCs Hematopoietic stem cells
IGFs Insulin-like growth factors
ILs Interleukins
MFBs Myofibroblasts
MMPs Matrix metalloproteinases
OB-BMST Osteoblastic bone metastasis-associated stroma transcriptome
PCa Prostate cancer
PDGFR Platelet-derived growth factor receptor
PIA Proliferative inflammatory atrophy
PIN Prostatic intraepithelial neoplasia
POSTN Periostin
PSA Prostate-specific antigen
ROS Reactive-oxygen species
TGF-β Transforming growth factor -β
TGFβRII TGF-β receptor type II
TIMPs Tissue inhibitors of matrix metalloproteinases
TME Tumor microenvironment
TNC Tenascin C
VEGF Vascular endothelial growth factor
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